New Zealand clears two psychiatrists to prescribe MDMA

New Zealand’s medicines regulator Medsafe has authorised two psychiatrists to prescribe pharmaceutical-grade MDMA, combined with psychotherapy, to patients with post-traumatic stress disorder. The decision was announced on 4 September 2026 by David Seymour, Associate Minister of Health.

The scope is narrow and worth stating precisely. MDMA remains an unapproved medicine in New Zealand; what changed is that two named clinicians may now prescribe it. Treatment happens inside the prescriber’s clinic as part of a comprehensive treatment plan, and patients cannot take the drug home. That constraint is the mechanism: the psychotherapy is not an adjunct to the dose, it is the setting the dose is licensed for.

Seymour said the changes put New Zealand’s settings in line with Australia, where authorised prescribers have been providing MDMA-assisted psychotherapy for PTSD in clinical settings for some time. The announcement does not name the two clinicians or the pathway under which the authority was granted.

Regulators approving a psychedelic for a psychiatric indication is a question of who is allowed to access a treatment, not of what the treatment can do. Here the answer, for now, is the patients of two doctors.